160 related articles for article (PubMed ID: 20516282)
1. Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteers.
Shaw JP; Cheong J; Goldberg MR; Kitt MM
Antimicrob Agents Chemother; 2010 Aug; 54(8):3365-71. PubMed ID: 20516282
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
Darwish M; Nunez R; Youakim JM; Robertson P
Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349
[TBL] [Abstract][Full Text] [Related]
3. Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin.
Goldberg MR; Wong SL; Shaw JP; Kitt MM; Barriere SL
Pharmacotherapy; 2010 Jan; 30(1):35-42. PubMed ID: 20030471
[TBL] [Abstract][Full Text] [Related]
4. Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects.
Wong SL; Goldberg MR; Ballow CH; Kitt MM; Barriere SL
Pharmacotherapy; 2010 Feb; 30(2):136-43. PubMed ID: 20099988
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, Disposition, and Biotransformation of [
Weber E; Subramanian R; Rowe W; Graupe M; Ling J; Shen G; Begley R; Sager J; Wolckenhauer S; Rhee M; Palaparthy R; Singh R
Clin Pharmacokinet; 2024 Feb; 63(2):241-253. PubMed ID: 38236562
[TBL] [Abstract][Full Text] [Related]
6. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects.
Wong SL; Barriere SL; Kitt MM; Goldberg MR
J Antimicrob Chemother; 2008 Oct; 62(4):780-3. PubMed ID: 18586659
[TBL] [Abstract][Full Text] [Related]
7. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
[TBL] [Abstract][Full Text] [Related]
8. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
Gotfried MH; Shaw JP; Benton BM; Krause KM; Goldberg MR; Kitt MM; Barriere SL
Antimicrob Agents Chemother; 2008 Jan; 52(1):92-7. PubMed ID: 17923490
[TBL] [Abstract][Full Text] [Related]
9. Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men.
Cirillo I; Mannens G; Janssen C; Vermeir M; Cuyckens F; Desai-Krieger D; Vaccaro N; Kao LM; Devineni D; Redman R; Turner K
Antimicrob Agents Chemother; 2008 Oct; 52(10):3478-83. PubMed ID: 18644951
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, absorption, metabolism, and excretion of [
Prakash C; Fan B; Altaf S; Agresta S; Liu H; Yang H
Cancer Chemother Pharmacol; 2019 May; 83(5):837-848. PubMed ID: 30758648
[TBL] [Abstract][Full Text] [Related]
11. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study.
Tiseo PJ; Perdomo CA; Friedhoff LT
Br J Clin Pharmacol; 1998 Nov; 46 Suppl 1(Suppl 1):19-24. PubMed ID: 9839761
[TBL] [Abstract][Full Text] [Related]
12. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil.
Muirhead GJ; Rance DJ; Walker DK; Wastall P
Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):13S-20S. PubMed ID: 11879255
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and metabolism of single oral doses of trovafloxacin.
Vincent J; Teng R; Dalvie DK; Friedman HL
Am J Surg; 1998 Dec; 176(6A Suppl):8S-13S. PubMed ID: 9935250
[TBL] [Abstract][Full Text] [Related]
14. Revefenacin Absorption, Metabolism, and Excretion in Healthy Subjects and Pharmacological Activity of Its Major Metabolite.
Bourdet DL; Yeola S; Hegde SS; Colson PJ; Barnes CN; Borin MT
Drug Metab Dispos; 2020 Dec; 48(12):1312-1320. PubMed ID: 32978223
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and excretion of
van Andel L; Fudio S; Rosing H; Munt S; Miguel-Lillo B; González I; Tibben MM; de Vries N; de Vries Schultink AHM; Schellens JHM; Beijnen JH
Invest New Drugs; 2017 Oct; 35(5):589-598. PubMed ID: 28111728
[TBL] [Abstract][Full Text] [Related]
16. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.
Lodise TP; Gotfried M; Barriere S; Drusano GL
Antimicrob Agents Chemother; 2008 Jul; 52(7):2300-4. PubMed ID: 18426898
[TBL] [Abstract][Full Text] [Related]
17. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.
Gerisch M; Hafner FT; Lang D; Radtke M; Diefenbach K; Cleton A; Lettieri J
Cancer Chemother Pharmacol; 2018 Jan; 81(1):195-206. PubMed ID: 29188322
[TBL] [Abstract][Full Text] [Related]
18. Tissue pharmacokinetics of telavancin in healthy volunteers: a microdialysis study.
Matzneller P; Österreicher Z; Reiter B; Lackner E; Stimpfl T; Zeitlinger M
J Antimicrob Chemother; 2016 Nov; 71(11):3179-3184. PubMed ID: 27494910
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers.
Blight AR; Henney HR
Clin Ther; 2009 Feb; 31(2):328-35. PubMed ID: 19302905
[TBL] [Abstract][Full Text] [Related]
20. Mass balance, metabolic disposition, and pharmacokinetics of [
Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F
Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
